<DOC>
	<DOCNO>NCT02244372</DOCNO>
	<brief_summary>The investigator perform randomize , double-blind , placebo-controlled human trial evaluate efficacy safety Cordyceps sinensis mycelium culture extract ( Paecilomyces hepiali , CBG-CS-2 ) promotion immunity . The investigator measure promotion immunity parameter , include Cytotoxicity , Cytokine ( IL-4 , IL-6 , IL-12 , IFN-γ , TNF-α ) , hs-CRP , antibody titer , upper respiratory tract infection ( URI )</brief_summary>
	<brief_title>Efficacy Safety Cordyceps Sinensis Mycelium Culture Extract ( Paecilomyces Hepiali , CBG-CS-2 ) Promotion Immunity</brief_title>
	<detailed_description />
	<criteria>Males female 2080 year old Who suffer twice Upper respiratory infection* disorder common cold causing URI Able give inform consent WBC concentration 3000 ㎕ Subjects vaccinate influenza within last 6 month prior study Subjects Upper respiratory infection screen visit Subjects BMI ＜ 18.5 kg/m2 screen visit Allergic hypersensitive ingredient test product Diagnosed gastrointestinal disease Immunerelated diseases , severe hepatic , renal failure , diabetes History reaction test product gastrointestinal disease Crohn 's disease gastrointestinal surgery History alcohol substance abuse Participation clinical trial within past 2 month Laboratory test , medical psychological condition deem investigator interfere successful participation study Pregnant lactate woman etc .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cordyceps sinensis mycelium culture extract ( Paecilomyces hepiali , CBG-CS-2 )</keyword>
	<keyword>immunity</keyword>
</DOC>